In conclusion, due to the high level of phosphorylation of YB-1 in tumor tissues from CRC patients, cotargeting YB-1 and Akt is a suitable approach to reduce cell proliferation in CRC cells, independent of KRAS mutational status. The gene discussed is AKT1; the disease is neoplasm.